

least about 90% (w/w) of the isoflavone content and genistein, if present, is in the amount of about 5% (w/w) or less.

B1  
Entry

34. A method according to claim 33 wherein the formononetin represents at least about 95% of the isoflavone content.

35. A method according to claim 33 wherein the formononetin represents at least about 98% of the isoflavone content.

36. A method according to claim 33 wherein genistein is less than about 1% (w/w) with regard to isoflavone content.

37. A method according to claim 33 wherein the isoflavone composition is administered at least once per day.

38. A method according to claim 33 wherein the isoflavone composition is administered in an amount from about 5 mg/day through to about 400 mg/day.

39. A method according to claim 33 wherein the isoflavone composition is administered from 1 to 6 times in a 24 hour period so as to give a daily dosage of from about 5 to about 400 mg.

40. A method according to claim 33 wherein the isoflavone composition is derived from a plant extract.

41. A method according to claim 33 wherein the formononetin is accompanied by one or more pharmaceutically acceptable adjuvants, carriers and or excipients.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

42. A method according to claim 33 which is a method for the treatment or prevention of menopausal symptoms in a post-menopausal woman.

43. A method according to claim 42 wherein the menopausal symptoms comprise one or more of hot flushes, sweating at night, heart beating quickly or strongly, feelings of tension or nervousness, difficulty in sleeping, excitability, attacks of panic, difficulties in concentrating, feelings of tiredness or lack of energy, unhappiness or depression, crying spells, irritability, feelings of dizziness or faintness, pressure or tightness in head or body, parts of the body feeling numb or tingling, dry vagina and/or dry mouth, headaches, muscle and joint pains, loss of feeling in hands or feet, breathing difficulties, loss of interest in sex, and loss of bone density.

44. A method for the treatment or prevention of menopausal symptoms in a post-menopausal woman, said method comprising administering to the woman an effective amount of an isoflavone composition comprising formononetin and daidzein.


45. A method according to claim 44 wherein the ratio of formononetin to daidzein is from about 1:10 to 10:1.

46. A method according to claim 44 wherein the formononetin represents at least about 90% of the isoflavone content.

47. A method according to claim 44 wherein the isoflavone composition further comprises one or more of the isoflavones biochanin and genistein, and genistein, if present, is in the amount of about 5% or less.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

- 
48. A method according to claim 47 wherein genistein is less than about 1% (w/w) with regard to isoflavone content.
49. A method according to claim 44 wherein the isoflavone composition is administered at least once per day.
50. A method according to claim 44 wherein the isoflavone composition is administered in an amount from about 5 mg/day through to about 400 mg/day.
51. A method according to claim 44 wherein the isoflavone composition is administered from 1 to 6 times in a 24 hour period so as to give a daily dosage of from about 5 to about 400 mg.
52. A method according to claim 44 wherein formononetin and daidzein are derived from a plant extract.
53. A method according to claim 44 wherein the isoflavone composition includes one or more pharmaceutically acceptable adjuvants, carriers and or excipients.
54. A method according to claim 44 wherein the daidzein is a daidzein metabolite selected from equol, o-desmethylangolensin, dehydroequol, 2-dehydro-o-desmethylangolensin, 6-hydroxy-o-desmethylangolensin, dihydrodaidzein and tetrahydrodaidzein.
55. A method according to claim 44 wherein the daidzein is in the aglycone, glycoside, malonyl or acetyl form.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

B1  
Carter

56. A method according to claim 44 wherein the menopausal symptoms comprise one or more of hot flushes, sweating at night, heart beating quickly or strongly, feelings of tension or nervousness, difficulty in sleeping, excitability, attacks of panic, difficulties in concentrating, feelings of tiredness or lack of energy, unhappiness or depression, crying spells, irritability, feelings of dizziness or faintness, pressure or tightness in head or body, parts of the body feeling numb or tingling, dry vagina and/or dry mouth, headaches, muscle and joint pains, loss of feeling in hands or feet, breathing difficulties, loss of interest in sex, and loss of bone density.

57. A method for the treatment or prevention of menopausal symptoms in a post-menopausal woman, said method comprising administering to the woman an effective amount of an isoflavone composition comprising formononetin in association with one or more of biochanin or genistein where the levels of said one or more of biochanin or genistein are each less than about 10% w/w or less of the isoflavone content, and wherein genistein, if present, is in the amount of less than about 5% w/w.

58. A method according to claim 57 wherein the formononetin represents at least about 90% of the isoflavone content.

59. A method according to claim 57 wherein genistein, if present, is less than about 1% (w/w) with regard to isoflavone content.

60. A method according to claim 57 wherein the isoflavone composition is administered at least once per day.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

B1  
Amy

61. A method according to claim 57 wherein the isoflavone composition is administered in an amount from about 5 mg/day through to about 400 mg/day.
62. A method according to claim 57 wherein the isoflavone composition is administered from 1 to 6 times in a 24 hour period so as to give a daily dosage of from about 5 to about 400 mg.
63. A method according to claim 57 wherein the formononetin is derived from a plant extract.
64. A method according to claims 57 wherein the isoflavone composition includes one or more pharmaceutically acceptable adjuvants, carriers and or excipients.
65. A method according to claim 57 wherein the menopause symptoms comprise one or more of hot flushes, sweating at night, heart beating quickly or strongly, feelings of tension or nervousness, difficulty in sleeping, excitability, attacks of panic, difficulties in concentrating, feelings of tiredness or lack of energy, unhappiness or depression, crying spells, irritability, feelings of dizziness or faintness, pressure or tightness in head or body, parts of the body feeling numb or tingling, dry vagina and/or dry mouth, headaches, muscle and joint pains, loss of feeling in hands or feet, breathing difficulties, loss of interest in sex, and loss of bone density.
66. A composition for the treatment or prevention of menopausal symptoms, said composition comprising an effective amount of the isoflavone formononetin, wherein formononetin represents at least about 90% (w/w) of the isoflavone content and genistein, if present, is in the amount of about 5% (w/w) or less.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

67. A composition according to claim 66 wherein the formononetin represents at least about 95% of the isoflavone content.

68. A composition according to claim 66 wherein the formononetin represents at least about 98% of the isoflavone content.

69. A composition according to claim 66 wherein genistein, if present, is less than about 1% (w/w) with regard to isoflavone content.

70. A composition according to claim 66 wherein the formononetin is derived from a plant extract.

71. A composition according to claim 66 further comprising one or more pharmaceutically acceptable adjuvants, carriers and or excipients.

72. A composition according to claim 66 which is a composition for the treatment of symptoms of menopause in a post-menopausal woman.

73. A composition for the treatment or prevention of menopausal symptoms in a post-menopausal woman, said composition comprising an effective amount of formononetin in association with one or more of biochanin or genistein where the levels of said one or more of biochanin or genistein are each less than about 10% w/w or less of the isoflavone content, and wherein genistein, if present, is in the amount of less than about 5% w/w.

74. A composition according to claim 73 wherein the formononetin represents at least about 90% of the isoflavone content.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

75. A composition according to claim 73 wherein the formononetin represents at least about 95% of the isoflavone content.
76. A composition according to claim 73 wherein genistein, if present, is less than about 1% (w/w) with regard to isoflavone content.
77. A composition according to claim 73 wherein the formononetin is derived from a plant extract.
78. A composition according to claim 73 further comprising one or more pharmaceutically acceptable adjuvants, carriers and or excipients.
79. A composition according to claim 73 wherein daidzein, if present, is a daidzein metabolite selected from equol, o-desmethylangolensin, dehydroequol, 2-dehydro-o-desmethylangolensin, 6-hydroxy-o-desmethylangolensin, dihydrodaidzein and tetrahydrodaidzein.
80. A composition according to claim 79, wherein the daidzein is in the aglycone, glycoside, malonyl or acetyl form.
81. A composition for the treatment or prevention of menopausal symptoms, said composition comprising an effective amount of the isoflavones daidzein and formononetin in combination, wherein the ratio of formononetin to daidzein is about 1:10 to 10:1 and genistein, if present, is in the amount of about 5% (w/w) or less.
82. A composition according to claim 81 wherein genistein, if present, is less than about 1% (w/w) with regard to isoflavone content.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

83. A composition according to claim 81 wherein the daidzein and formononetin are derived from a plant extract.

84. A composition according to claim 81 further comprising one or more pharmaceutically acceptable adjuvants, carriers and or excipients.

85. A composition according to claim 81 wherein daidzein is a daidzein metabolite selected from equol, o-desmethylangolensin, dehydroequol, 2-dehydro-o-desmethylangolensin, 6-hydroxy-o-desmethylangolensin, dihydrodaidzein and tetrahydrodaidzein.

86. A composition according to claim 81 wherein the daidzein is in the aglycone, glycoside, malonyl or acetyl form.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com